3 Stocks To Buy And Hold For The Next Decade: Eli Lilly, HCA Healthcare, And Seagen

If there is one lesson the COVID-19 pandemic has taught humanity, it is to value our health over all else. As such, healthcare now tops most people’s priority lists, and companies that offer products and services in this sector are flourishing.

The Centers for Medicare & Medicaid Services’ Office of the Actuary’s preliminary projections state that national healthcare spending in the U.S. will increase to $6.2 trillion by 2028. Reviving Obamacare and implementing measures to offer subsidized healthcare to all Americans are among the Biden administration’s major plans.

So. we think Pharmaceutical companies, hospital operators, and biotechnology players are all poised to see spectacular growth.  Because of the sector’s growing importance, investors can now consider healthcare stocks fundamentally sound for the long term.

We view Eli Lilly and Company (LLY - Get Rating), HCA Healthcare, Inc. (HCA - Get Rating), and Seagen, Inc. (SGEN - Get Rating) as three of the best-performing healthcare stocks in terms of their business models and financials.

Eli Lilly and Company (LLY - Get Rating)

LLY is one of the top pharmaceutical companies. It offers endocrinology products to treat diabetes and osteoporosis in men and postmenopausal women. It has also developed a cure for human growth hormone deficiency and pediatric growth conditions. LLY also has a collaboration with Junshi Biosciences to develop therapeutic antibodies for the potential prevention and treatment of COVID-19.

The U.S. FDA has granted Emergency Use Authorization (EUA) to LLY’s antibody therapies for Covid-19, which has been developed in collaboration with AbCellera. The latest authorization comes from Phase III data from the BLAZE-1 trial, which demonstrated that the combination therapy reduced the risk of COVID-19 hospitalizations and death by 70%.

During the fourth quarter ended December 2020, LLY’s revenue grew 21.7% year-over-year to $7.4 billion, driven by a 24% increase in volume and a 1% increase due to the favorable impact of foreign exchange rates. The company also recognized $871.2 million in revenue from bamlanivimab, its COVID-19 antibody therapy. Its  EPS for the quarter climbed to $2.75 compared to $1.73 posted in the same period last year.

1 2 3 4
View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Beating Buffett 2 weeks ago Member's comment

Completely agree with $LLY (executive shenanigans aside) 📈